News Releases

DALLAS, May 05, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that Mei Mei Hu, President and Chief Executive Officer of Vaxxinity, will participate in a fireside chat at the Bank of

DALLAS, May 02, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a company pioneering the development of a new class of immunotherapeutic vaccines, today announced that UB-311, an anti-amyloid beta immunotherapeutic vaccine, has been granted Fast Track designation by the U.S.

Results from UB-312’s Part A first-in-human trials published in Movement Disorders DALLAS, April 28, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced it has completed patient enrollment

OSLO, Norway and DALLAS, April 06, 2022 (GLOBE NEWSWIRE) -- The Coalition for Epidemic Preparedness Innovations (CEPI) and Vaxxinity, Inc. (Nasdaq: VAXX), a US company pioneering the development of a new class of immunotherapeutic vaccines, today announced that they will co-fund the ongoing global

Pivotal Phase 3 head-to-head study will evaluate non-inferiority of heterologous booster candidate UB-612 against authorized mRNA, adenovirus vector and inactivated virus COVID-19 vaccines Agreement reached with global regulators on trial design and data package required to support potential

DALLAS, March 24, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2021.

DALLAS, March 21, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines for chronic diseases, today announced that Peter Powchik, M.D. is joining its Board of Directors and will be retiring as Vaxxinity’s

Investigator-sponsored studies show UB-612 induces high antibody activity against multiple variants, including Alpha, Beta, Delta, Gamma and Omicron, at levels similar to or higher than approved vaccines UB-612 elicits >3 times higher titers of neutralizing antibodies against Omicron variant than

DALLAS, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that the first patient with Parkinson’s disease (PD) has been dosed with UB-312 in Part B of a double-blinded,

DALLAS, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ: VAXX), a clinical-stage biotech company pioneering a new class of immunotherapeutic vaccines to treat and prevent chronic neurological diseases, including Alzheimer’s and Parkinson’s, has announced that the company has been awarded